Adverse effects of imatinib in children with chronic myelogenous leukemia

© 2016 Japan Pediatric Society Background: Imatinib mesylate (IM) is a selective tyrosine kinase inhibitor and is approved for indefinite treatment of pediatric chronic myelogenous leukemia (CML). Potential side-effects regarding growth failure and bone metabolism have been reported but data are sti...

Full description

Saved in:
Bibliographic Details
Main Authors: Worawut Choeyprasert, Thitinun Yansomdet, Rungrote Natesirinilkul, Karn Wejaphikul, Pimlak Charoenkwan
Format: Journal
Published: 2018
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85005810433&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/47216
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University